2018 AANS Annual Scientific Meeting-623. Trial of Convection-Enhanced Delivery of Muscimol in Patients with Medically-Intractable Epilepsy

623. Trial of Convection-Enhanced Delivery of Muscimol in Patients with Medically-Intractable Epilepsy

Video Transcription

Video Summary

In this video presentation, Dr. David Argersinger discusses a study on the convection-enhanced delivery of mucemol in patients with drug-resistant epilepsy. The study aims to investigate the safety and effectiveness of mucemol infusion into the epileptic focus of patients. The research involves three patients with drug-resistant epilepsy who did not adequately improve with anti-epileptic drugs. Convection-enhanced delivery is a minimally invasive treatment that bypasses the blood-brain barrier and selectively targets the brain's extracellular space. The study found that mucemol infusion reduced seizure frequency in one out of three patients, and there were no adverse effects on seizure surgery outcome. The researchers recommend the use of a surrogate tracer for better visualization of fluid distribution in future trials. The study was funded by the Intramural Research Program at the NIH.

Asset Caption

Davis Palmer Argersinger, B.S.

Keywords

convection-enhanced delivery

mucemol

drug-resistant epilepsy

seizure frequency

surrogate tracer